Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)

Sponsor
Boston Scientific Corporation (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04032470
Collaborator
(none)
500
12
110.3
41.7
0.4

Study Details

Study Description

Brief Summary

To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of Essential Tremor.

Condition or Disease Intervention/Treatment Phase
  • Device: Deep Brain Stimulation Systems (DBS)

Detailed Description

To compile characteristics of real-world outcomes using Deep Brain Stimulation (DBS) for the treatment of Essential Tremor to add to the evidence available for treatment of ET.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Boston Scientific Registry of Deep Brain Stimulations for Treatment of Essential Tremor (ET):ET Registry
Actual Study Start Date :
Oct 23, 2019
Anticipated Primary Completion Date :
Dec 31, 2028
Anticipated Study Completion Date :
Dec 31, 2028

Arms and Interventions

Arm Intervention/Treatment
Essential Tremor

Subjects with Essential Tremor being implanted with Boston Scientific Deep Brain Stimulation Systems

Device: Deep Brain Stimulation Systems (DBS)
Subjects receiving DBS implant for treatment of Essential Tremor

Outcome Measures

Primary Outcome Measures

  1. Change in Quality of Life during the study as compared with baseline using the Quality of Life in Essential Tremor Questionnaire (QUEST) [Up to 3 years]

    Change in quality of life over the course of the study using QUEST

Other Outcome Measures

  1. Change in tremor scores during the study as compared with baseline as assessed by Fahn-Tolosa- Marin Rating Scale [Up to 3 years]

    Improvement in tremor scores as assessed by Fahn-Tolosa-Marin Tremor Rating Scale (FTMTRS) during the study as compared with baseline

  2. Impression of Change scores during the study using Global Impression of Change [Up to 3 years]

    Impression of Change scores during the study using Global Impression of Change

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Meets criteria established in the locally applicable Directions for Use (DFU) for Essential Tremor

  • Is at least 18 years old

Exclusion Criteria:
  • Meets any contraindication in locally applicable Directions for Use

Contacts and Locations

Locations

Site City State Country Postal Code
1 AZ Sint-Lucas Gent Belgium
2 AZ Delta Roeselare Belgium
3 Uniklinik Koln Cologne Germany
4 Universitatsklinikum Campus Kiel Kiel Germany
5 Universitaetsklinikum Wuerzburg Würzburg Germany
6 Medical School of University PECS Pécs Hungary
7 Policlinico Universitario Agostino Gemelli Rome Italy
8 Samsung Medical Center Seoul Korea, Republic of
9 Seoul ASAN Medical Center Seoul Korea, Republic of
10 CHU Sao Joao Porto Portugal
11 Hospital De Bellvitge Barcelona Spain 30326
12 Hospital General De Asturias Oviedo Spain

Sponsors and Collaborators

  • Boston Scientific Corporation

Investigators

  • Study Director: Roshini Jain, Boston Scientific Corporation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT04032470
Other Study ID Numbers:
  • A4080
First Posted:
Jul 25, 2019
Last Update Posted:
Aug 10, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Boston Scientific Corporation
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 10, 2022